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Whey protein lowers systolic blood 
pressure and Ca-caseinate reduces 
serum TAG after a high-fat meal in 
mildly hypertensive adults
Ágnes A. Fekete1,2, Carlotta Giromini  3, Yianna Chatzidiakou1, D. Ian Givens2 &  
Julie A. Lovegrove  1,2
Epidemiological studies show an inverse association between dairy consumption and blood pressure 
(BP) but there are few data on the postprandial effects of milk proteins. This study examined their 
effects, compared to maltodextrin, on postprandial BP and other CVD risk markers in volunteers 
with mild and pre-hypertension over an 8 h period. In this double-blinded, randomised, cross-over, 
controlled study 27 adults ingested a high-fat, isoenergetic breakfast and lunch with 28 g whey 
protein, 28 g Ca-caseinate or 27 g maltodextrin. Whey protein reduced systolic BP compared with 
Ca-caseinate (−15.2 ± 13.6 mmHg) and maltodextrin (−23.4 ± 10.5 mmHg) up to 5 h post-ingestion. 
There was an improvement in arterial stiffness after whey protein compared with maltodextrin 
(incremental Area Under the Curve- iAUC0–8h: +14.4 ± 6.2%). Despite similar glucose levels after 
both whey protein and Ca-caseinate, whey protein induced a higher insulin response than Ca-
caseinate (iAUC0–8h: +219.5 ± 54.6 pmol/L). Ca-caseinate induced less suppression of non-esterified 
fatty acids than whey protein (iAUC0–5h: −58.9 ± 135.5 μmol/L) and maltodextrin (iAUC0–5h: 
−106.9 ± 89.4 μmol/L) and induced a smaller postprandial triacylglycerol response than whey protein 
(iAUC0–8h: −1.68 ± 0.6 mmol/L). Milk proteins co-ingestion with high-fat meals may have the potential 
to maintain or improve CVD risk factors.
High blood pressure (BP) (≥140/90 mmHg) has been considered one of the major killers worldwide1 and is an 
important modifiable risk factor for CVD, among other classic risk factors such as high blood cholesterol, obesity, 
and smoking2. Arterial stiffness and endothelial dysfunction provide important information on the progression 
of atherosclerosis and are recognized as novel, independent risk markers of CVD3. Diet is a key modulator of 
CVD risk and epidemiological studies have identified a beneficial association between milk and dairy, particu-
larly fermented dairy (cheese and yoghurt) consumption and CVD risk factors, specifically BP4,5. The particular 
components of milk and dairy that are associated with these reported beneficial effects are not fully elucidated, 
but dairy proteins and bioactive peptides have been proposed as important mediators6,7. In order to investigate 
the effects and underlying mechanisms of milk protein consumption and the vascular system, we previously per-
formed a chronic randomised controlled dietary intervention study to investigate the long-term effects of intact 
milk proteins on BP and other CVD risk markers compared with carbohydrate8. We found that whey protein and 
Ca-caseinate supplementation resulted in improvements in several cardiometabolic risk factors, such as 24-h BP, 
arterial reactivity, blood lipids and some markers of vascular function, in fasted subjects over an 8-wk interven-
tion period compared with a carbohydrate supplement8. However, it is of note that in Western countries, people 
spend considerable time (approximately 18 h/day) in a postprandial state, as a result of the frequent meal and 
snack intake. The postprandial period is considered to be an important contributing factor to chronic diseases 
such as atherosclerosis or diabetes9. Emerging evidence suggests that elevated postprandial triacylglycerol (TAG) 
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concentrations  play an important role in the pathogenesis of CVD and is now considered as an independent risk 
factor for CVD10. Due to frequent meal consumption throughout the day, plasma TAG often does not return to 
fasted concentrations until early morning. Therefore, it is prudent to investigate potential dietary strategies to 
mitigate the metabolic disturbances that occur after food ingestion, such as hyperglycaemia and hypertriacylg-
lycerolaemia. Whey protein has been shown to lower postprandial TAG in a limited number of RCTs11,12, while 
its effects on acute glucose metabolism have included increased plasma insulin levels and reduced peak plasma 
glucose compared with casein11–17.
Furthermore, there is a marked diurnal variation in BP among those with hypertension, with a surge in the 
morning, which if exaggerated, is a risk factor for stroke, independent of 24-h BP18. Similarly, post-waking blunt-
ing of flow-mediated dilation (FMD), a gold standard measure of macrovascular function, is an independent 
predictor of adverse cardiovascular events19. Therefore it is of clinical importance to determine whether dairy 
proteins can acutely reduce BP and improve vascular function, and thus exert beneficial effects during this period 
of increased risk. However, to the best of our knowledge, the only RCT which investigated the acute effects of 
dairy proteins on the cardiovascular system failed to find any acute changes in BP or augmentation index (AI) 
after whey protein or Na-caseinate ingestion in a 6 h postprandial study20.
The aim of this study was to test the hypothesis that the ingestion of milk proteins: whey protein and 
Ca-caseinate, with a high-fat isoenergetic breakfast and lunch will result in a reduced postprandial BP and 
improvements in vascular function and other CVD risk markers in adults with pre- and mild hypertension com-
pared with carbohydrate (maltodextrin) over an 8-h postprandial period.
Subjects and Methods
Participants. A total of 30, healthy, non-smoking men and women with mildly elevated BP of 120/80-
159/99 mmHg, aged 30–77 y, not taking antihypertensive or cholesterol-lowering medications were recruited for 
this trial from local communities through database, local newspapers and electronic advertisements. This study 
was conducted at the Hugh Sinclair Unit of Human Nutrition, University of Reading, between February 2014 and 
February 2015. Participants were selected if they met the inclusion criteria of BP: 120/80-159/99 mmHg, 30–77 y 
old, BMI 20–40 kg/m2, fasted glucose <7 mmol/L (not diagnosed with diabetes), cholesterol <8 mmol/L, TAG 
<4 mmol/L, normal liver and kidney function, and haemoglobin >110 g/dl and >140 g/dl (for women and men, 
respectively). Subjects provided written informed consent prior to enrolment onto the study and eligibility or 
exclusion was assessed by the study researcher based on a phone interview questionnaire, followed by a screening 
visit. Participants were excluded based on the following criteria: milk allergy or lactose intolerance, diabetes, 
coeliac disease, renal, gastrointestinal, respiratory, endocrine, liver disease or cancer, surgery in the previous six 
months, secondary hypertension, excess alcohol consumption (drinking >280 ml ethanol/wk and >210 ml etha-
nol/wk, for men and women, respectively), smokers, vegan, taking nutritional supplement (including fish oil, pro-
tein shakes, vitamins), anaemia, pregnancy, lactation or planning pregnancy. Blood donation three months before 
or during the study was not permitted. The sample size was determined from previous results from our research 
group21 and sufficient to detect a 13 mmHg difference in our primary outcome (BP) between groups with a SD of 
14, at 90% power, and 5% significance level. A total of 24 participants were required to complete the study, but to 
account for 20% drop-out a total of 30 participants were recruited. The current study was also powered based on 
the study of Ballard et al.22 for the secondary outcome (FMD). To detect a 4.3% FMD intergroup difference with 
a SD of 2.3 at 90% power and 5% significance level, a total of six participants were required.
Study design. The trial was conducted according to the ethical standards laid down in the 1964 Declaration 
of Helsinki and the Research Ethics Committee at the University of Reading (Research Ethics Committee Project 
No. 12/40) gave approval for the study to be conducted. All experiments were performed in accordance with 
the relevant guidelines. The study was registered with the clinicaltrials.org (NCT02090842, registered on 17th 
June 2013). This trial was a randomised, double-blinded, controlled, three-way cross-over, acute dietary inter-
vention study with a 2-wk run-in period prior to the beginning of the trial. The study design is presented in 
Supplementary Figure 1. The volunteers were randomised by an independent researcher using an Excel-based 
randomisation program23, who was also responsible for treatment allocation. Equal numbers of volunteers were 
allocated to six treatment sequences (ABC, ACB, BAC, BCA, CAB and CBA). A double-blinded protocol was 
maintained throughout the study, during sample analysis and statistical analysis, the codes for the study drinks 
were kept under lock at Volac Int. Ltd. (Cambridge) and University of Reading.
The primary outcome was postprandial, 8 h BP, secondary outcomes were vascular reactivity measured by 
FMD, changes in plasma lipids, markers of insulin resistance, arterial stiffness measured by pulse wave analysis 
(PWA) and digital volume pulse (DVP).
Study drinks and test meals. The test meals consisted of a breakfast (at time 0) and a lunch (at time 
330 min). The breakfast included 75 g croissants (All Butter Mini Croissants, ASDA), 15 g butter (ASDA), four 
pieces of shortbread fingers (Paterson’s); the lunch consisted of 125 g white-bread (Kingsmill Soft White Bread), 
25 g butter (ASDA), 40 g Philadelphia soft cheese spread (Kraft Foods Limited). The test meals were isoener-
getic and each of them also consisted of either 28 g whey protein (Volac Int Ltd, Cambridge) or Ca-caseinate 
(Garret Ingredients, Thornbury); or 27 g maltodextrin (carbohydrate; MyProtein, Northwich), which were mixed 
with 250 ml low-nitrate water (Buxton Mineral water, Nestlé Waters UK) and 0.5 g sugar-free vanilla flavour 
(Myprotein, Northwich). For nutrient composition of the study drinks, see our previous publication8, and for the 
acute test meal nutrients composition, see Supplementary Table 1, which was based on the DISRUPT study24 with 
higher protein content in this trial.
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Study visits. The detailed protocol for the screening visit has been published elsewhere8. Two weeks prior to 
the first intervention study day, all participants attended a familiarisation visit (Visit 0) at the Hugh Sinclair Unit 
of Human Nutrition in order to familiarise volunteers with the environment and reduce the ‘white-coat effect’. 
This was a one-on-one session with the study researcher who thoroughly explained the procedure of the inter-
vention visits and the requirements for the day before the study days. All vascular techniques and their imple-
mentation were clearly explained and demonstrated to the participants. Volunteers were asked to refrain from 
alcohol consumption and strenuous exercises 24-h before visits, and at the commencement of each study visit 
they had to orally confirm compliance to this protocol. Participants consumed a low-fat and low-protein meal the 
evening before visits that was provided to them and drank only low-nitrate water (Buxton Mineral water, Nestlé 
Waters UK). On the first study visit, participants drank ad libitum Buxton water. The time and amount of water 
consumption was recorded and the same amount was given at the same time on the following study visits in order 
to standardise water intake throughout the study. During acute study visits, upon arrival at the Unit, body weight 
and composition were measured as specified previously8. Participants then rested for 30 min in a supine position 
in a quiet, temperature-controlled room (20 °C ± 1) prior to vascular testing. All measurements were conducted 
by the same researcher (except automated DVP, which was taken by multiple trained researchers). These meas-
urements were repeated on three occasions during the day. After the baseline vascular measurements and before 
breakfast, a cannula was inserted into the antecubital vein in the left arm and a baseline blood sample was taken. 
Blood samples were then collected at 30-min intervals for 2 h and every 60 min for a further 3 h. After lunch (time 
330 min) blood was taken every half an hour for 1.5 h and then 60 min for an hour. Participants returned for the 
second and third arm of the study after a 3–4 wk washout period each. Premenopausal women attended all visits 
at the same phase of their menstrual cycle.
BP and assessments of vascular function. BP was measured on the left arm using a non-invasive auto-
matic BP monitor (TM-2430; A&D Ltd) according to the manufacturer’s instructions. The cuff-size was selected 
based on upper arm circumference measurements. Participants rested for at least 1 h before the BP monitors were 
fitted by one researcher (after baseline vascular measurements taken) and were removed after 8 h. All baseline BP 
measurements were taken in triplicate, after which the monitor was programmed to take the BP readings auto-
matically at 15 min intervals for a total period of 8 h. The vascular function tests were taken after the volunteers 
rested for 20 mins and in the following order: DVP, PWA, FMD at time 0, time 180 min, 300 min and 420 min. For 
further details on these assessments, see our previous publication8.
Biochemical analyses. Serum separator blood tubes were centrifuged at 1800 × g for 15 min at 20 °C 
(VACUETTE, Greiner Bio-One, UK); lithium heparin and ethylenediaminetetraacetic acid (EDTA) blood col-
lection tubes (VACUETTE, Greiner Bio-One, UK) were centrifuged at 1800 × g for 10 min at 4 °C. Samples were 
kept at −20 °C for further analyses. TAG, glucose and non esterified fatty acids (NEFA) were quantified in serum 
by using an autoanalyser (ILAB600, Werfen (UK) Ltd, Warrington, UK; reagents and analyser: Instrumentation 
Laboratory Ltd.; NEFA reagent: Alpha Laboratories). An ELISA kit was used to determine serum insulin (Dako 
Ltd.). Serum angiotensin-converting enzyme (ACE) activity was determined by a fluorometric assay as described 
elsewhere25.
Statistical analyses. Data were analysed using IBM SPSS Statistics version 21 and SAS version 9.4 (SAS 
Institute). Data checks for normality were performed using histograms and Q-Q plots using SPSS. The data from 
participants’ who withdrew from the study were excluded in the analysis as a per protocol analysis was used. The 
primary analysis of the data was by repeated measures ANOVA to identify significant time × treatment interac-
tions with Bonferroni correction to control for multiple comparisons using SPSS. As secondary data analysis, area 
under the curve (AUC) was calculated by the trapezium rule, which was subtracted from the fasting value to cal-
culate incremental AUC (iAUC). AUC were analysed by linear mixed-model ANOVA using the difference from 
fasting values as dependent variable and baseline values of the variable of interest, BMI, age, sex and intervention 
treatment as prognostic variables by SAS. P ≤ 0.05 was considered significant, two-tailed p-value was used. Data 
presented in the text, tables, and figures represent the arithmetic means ± SEMs.
Results
Participants. A total of 30 people were randomised to the study, of which three withdrew (n = 1 lost interest, 
n = 2 unsuitable vein integrity) (see Fig. 1. for flow-chart). The baseline characteristics of completing partic-
ipants can be seen in Table 1. The study drinks were well tolerated, however two volunteers discontinued the 
Ca-caseinate study-arm right before lunch due to feeling full and not being able to consume the second meal. 
Therefore data were collected from n = 27 volunteers until lunch (5 h), and n = 25 up to 8 h. The cannula failed 
on two participants in one of the study arms, therefore blood sample data were excluded from those participants, 
thus collecting data from n = 23 for 8 h and n = 26 until lunch (5 h) for blood analyses, apart from for ACE activity 
(which was significantly influenced by haemolysis), where n = 22.
Postprandial BP. There were no treatment or time × treatment effects on BP, pulse pressure and heart rate 
for the 8 h period. However there was a significant overall time × treatment effect (p = 0.029) on systolic BP (SBP) 
until 5 h (Fig. 2). Similarly, a significantly lower iAUC for SBP was observed for the consumption of whey protein 
compared with maltodextrin (p = 0.039) 5 h post-ingestion (Table 2).
Vascular function. There was a time × treatment effect on FMD 8 h post-ingestion (p = 0.014). Whey 
protein significantly increased %FMD at 5 h after breakfast compared with maltodextrin (p = 0.017) (Fig. 3). 
The iAUC for AI measured by PWA decreased after whey protein ingestion compared with maltodextrin both 
after 5 h (p = 0.028) and 8 h (p = 0.043). There were no treatment or time × treatment effects on peripheral and 
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central systolic, diastolic or mean pressure; however there was a tendency for significant time × treatment effect: 
Ca-caseinate lowered central SBP compared with maltodextrin 8 h post-ingestion (p = 0.052). No effect was seen 
on the stiffness index of DVP (Table 2).
Serum glucose, insulin and lipids. The 8 h postprandial serum glucose, insulin and lipid responses after 
whey protein, Ca-caseinate and maltodextrin co-ingestion with a high-fat meal are presented in Fig. 4. The iAUC 
for glucose was lower after whey protein and Ca-caseinate ingestion compared with maltodextrin (5 and 8 h 
post-ingestion, p < 0.001) (see Table 2). The iAUC for insulin increased following maltodextrin and whey pro-
tein consumption compared with Ca-caseinate at 5 h and 8 h post-ingestion (p < 0.001). The iAUC for NEFA 
showed treatment effect (p = 0.027) until 5 h: postprandial NEFA levels decreased between breakfast and lunch, 
the least suppression was seen after Ca-caseinate ingestion compared with whey protein and maltodextrin. No 
Figure 1. Participants inclusion flow-chart of the acute Whey2Go study.
N, male/female 27 (24/3)
Age, y 50.1 ± 2.3
BMI, kg/m2 27.3 ± 0.7
SBP, mmHg 133.2 ± 2.4
DBP, mmHg 81.5 ± 2.1
TC, mmol/L 5.09 ± 0.2
TAG, mmol/L 1.38 ± 0.1
Glucose, mmol/L 5.44 ± 0.1
Table 1. Baseline characteristics of participants1. 1BMI, body mass index; DBP, diastolic blood pressure; SBP, 
systolic blood pressure; TC, total cholesterol; TAG, triacylglycerol. Mean ± SEM.
www.nature.com/scientificreports/
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treatment or time × treatment effects were seen 8 h post-ingestion. There were significant treatment (p = 0.040) 
and time × treatment effects (p = 0.004) and differences in iAUC (p = < 0.001) for TAG where whey protein 
increased TAG concentration compared with Ca-caseinate and maltodextrin both 5 h and 8 h post-ingestion.
ACE activity. There was no treatment effect in iAUC or time × treatment interactions either 8 h or 5 h 
post-ingestion (Table 2).
Discussion
People in Western countries spend the majority of their time in a postprandial state, which is considered to be an 
important contributing factor to chronic diseases such as atherosclerosis and diabetes9. This novel study inves-
tigated whether an isoenergetic, high-fat breakfast and lunch consumed with either whey protein, Ca-caseinate 
compared with a carbohydrate source (maltodextrin), improved postprandial BP, vascular function, glucose, and 
lipid metabolism. We found that whey protein significantly decreased SBP 5 h post-ingestion compared with 
Ca-caseinate (−15.2 ± 13.6 mmHg) and carbohydrate (−23.4 ± 10.5 mmHg). Only one previous RCT evaluated 
the acute effects of milk proteins on BP, and their results were in contrast with ours. They found no effects of dairy 
proteins on BP20. The authors stated that the neutral results may have been due to the high fat content of their 
study meal (45% of total energy), yet our breakfast contained similar fat content (46% of total energy). However, 
even though they administered 45 g of whey protein or Na-caseinate at breakfast as opposed to 28 g of milk pro-
teins in our study, it is important to point out that Pal and Ellis20 used normotensive participants. It is therefore 
not surprising that no decrease in BP was observed in the previous study, as baseline BP has been shown to be an 
important moderator of hypotensive effects of milk proteins6,26.
One of the potential mechanisms of action that has been proposed for the hypotensive effects of milk proteins 
is ACE inhibition. Previously we reported that whey protein permeate expressed significantly higher ACE inhib-
itory activity in vitro compared with Ca-caseinate and maltodextrin8. Although we failed to identify treatment 
effects in serum ACE activity in this study, the direction of treatment effects whey>casein>maltodextrin is sup-
portive of the postprandial BP change. It is of note that high inter-individual variation was observed and greater 
study power may have been required to detect significant changes in serum ACE activity after milk protein inges-
tion, and should not be ruled out as a potential mechanism of action. Further research should aim to elucidate 
this issue. Whey protein attenuated the reduced vasodilation measured by FMD at 3 h post-ingestion, which was 
observed after Ca-caseinate and maltodextrin ingestion. At 5 h post-ingestion, FMD was significantly higher after 
whey protein ingestion compared with maltodextrin; whereas Ca-caseinate induced a gradual improvement in 
endothelial function between 3 and 5 h, and showed similar response to whey protein at 5 h post-ingestion. This 
may be due to the slower-release and absorption of Ca-caseinate, as opposed to whey protein, which is a so-called 
‘fast-release’ protein, being rapidly absorbed into the circulation27. Soop et al. suggested that the time-course of 
milk protein absorption should be considered, as casein may offer some advantages including prolonged appear-
ance of circulating amino acids, while whey protein is rapidly eliminated from the circulation28. It is speculative 
that Ca-caseinate may also have similar beneficial effects on endothelial function acutely, as seen in our chronic 
trial8, however somewhat delayed. A longer postprandial period is required to confirm this. Ballard et al. inves-
tigated the acute effects of a whey protein hydrolysate (NOP-47) in older individuals22. They found transient 
improvements in FMD (4.3 ± 0.5%) compared with placebo 120 min post-ingestion22, while we found only 0.60% 
improvements 300 min after breakfast. However, it is of note that the high-fat breakfast in the current study may 
have exerted significant deleterious effect on the endothelium and delayed the effect of whey protein due to slower 
gastric emptying.
Interestingly, despite the neutral effects of long-term whey protein consumption on arterial stiffness, whose 
measure is AI, in our chronic study8, we found a significant decrease of AI postprandially after whey protein 
ingestion compared with carbohydrate. In contrast, Pal and Ellis failed to show any effects of milk proteins on AI 
in their acute study20, however they reported a significant decrease of AI after 12-wk intervention that included 
2 × 27 g/d whey protein consumption compared with carbohydrate29. It is of note that, although AI is a meas-
ure of arterial stiffness (an independent predictor of cardiovascular risk), in a postprandial study it provides an 
estimation of central haemodynamics assessed by the shape of the pulse30. It has been demonstrated that AI can 
change postprandially, and this may be due to altered arterial smooth muscle relaxation in the splanchnic bed 
Figure 2. 8-h postprandial BP in men and women with pre- and mild hypertension after consuming whey 
protein, Ca-caseinate and maltodextrin. Values are means ± SEM, n = 25. ‡Whey protein vs. Ca-caseinate 
and maltodextrin p < 0.005; †Whey protein vs. maltodextrin p < 0.005; BP, blood pressure; ACE, angiotensin-
converting enzyme; iAUC, incremental area under the curve; RM, repeated-measure.
www.nature.com/scientificreports/
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in response to food intake, leading to neural or hormone-mediated smooth muscle relaxation in the general 
circulation31. Interestingly, previous research showed that insulin production after food intake in a postpran-
dial setting is the main determinant of arterial stiffness32,33. This is underpinned by our finding that whey pro-
tein induced increased insulin response, compared to Ca-caseinate, and similar to the magnitude observed after 
maltodextrin ingestion, especially after the second test meal, yet the maltodextrin did not reduce AI. Therefore, 
there may be other underlying mechanisms by which whey protein affects AI, which warrants further research. 
Furthermore, we observed similar serum glucose responses after whey protein and Ca-caseinate consumption, 
Baseline iAUC0–5h
p-value2
iAUC0–8h
p-value2
Whey 
protein
Ca-
aseinate
Maltodextrin 
rate Whey protein Ca-caseinate Maltodextrin Whey protein Ca-caseinate Maltodextrin
SBP, mmHg 136.6 ± 3.5 134.5 ± 3.5 135.5 ± 2.6 −26.9 ± 9.6a −11.6 ± 12.7a,b −3.5 ± 5.9b 0.039 −49.8 ± 15.0 −32.4 ± 19.3 −19.3 ± 9.1 0.101
DBP, mmHg 83.3 ± 2.5 81.5 ± 2.0 84.0 ± 2.3 −24.5 ± 4.6 −15.3 ± 5.6 −17.1 ± 5.6 0.117 −43.4 ± 7.0 −29.1 ± 7.9 −36.6 ± 9.0 0.182
PP, mmHg 51.8 ± 2.2 52.9 ± 2.3 48.7 ± 1.7 2.7 ± 8.6 2.9 ± 8.6 26.7 ± 8.1 0.696 7.35 ± 12.7 −3.1 ± 14.2 32.7 ± 11.6 0.342
Heart rate, 
b/min 59.5 ± 2.0 59.0 ± 2.1 59.6 ± 1.9 32.7 ± 4.1 32.9 ± 4.3 −31.1 ± 2.7 0.623 43.7 ± 6.5 44.9 ± 5.8 40.8 ± 4.4 0.844
AI@HR75, 
% 12.2 ± 2.2 10.8 ± 2.8 11.7 ± 2.7 −18.2 ± 2.7
a −13.8 ± 3.0a,b −9.1 ± 2.9b 0.028 −30.9 ± 4.4a −22.0 ± 4.9a,b −16.7 ± 4.5b 0.043
SI, % 8.15 ± 0.4 8.35 ± 0.5 8.15 ± 0.4 −0.75 ± 1.3 −2.71 ± 0.9 0.61 ± 0.7 0.065 −0.67 ± 2.1 −3.82 ± 1.5 0.24 ± 1.1 0.125
Glucose, 
mmol/L 5.10 ± 0.1 5.08 ± 0.1 5.03 ± 0.1 2.05 ± 0.3
a 1.87 ± 0.4a 4.03 ± 0.7b <0.001 4.40 ± 0.6a 4.08 ± 0.7a 9.74 ± 1.4b <0.001
Insulin, 
pmol/L 49.04 ± 5.3 45.26 ± 4.3 43.90 ± 4.6 767.6 ± 70.6
a 649.4 ± 63.2b 887.5 ± 83.6c <0.001 1346.6 ± 112.8a 1127.1 ± 111.4b 1482.7 ± 150.4a <0.001
NEFA, 
μmol/L 475 ± 45 496 ± 43 505 ± 37 −1015 ± 162
a −956 ± 147b −1063 ± 135a 0.027 −1337 ± 324 −1256 ± 284 −1488 ± 278 0.112
TAG, 
mmol/L 1.55 ± 0.2 1.49 ± 0.2 1.47 ± 0.2 3.57 ± 0.4
a 2.78 ± 0.3b 2.94 ± 0.4a 0.026 8.10 ± 0.8a 6.43 ± 0.7b 5.96 ± 0.8b <0.001
ACE activity, 
U/L 4.82 ± 0.2 4.61 ± 0.2 4.48 ± 0.2 −0.02 ± 0.4 0.41 ± 0.7 1.44 ± 0.7 0.338 −0.26 ± 0.6 0.71 ± 1.1 2.23 ± 1.3 0.398
Table 2. BP, vascular function measures and serum biochemistry of participants with pre- and mild 
hypertension at baseline, iAUC0–5h, and iAUC0–8h after whey protein, Ca-caseinate and maltodextrin 
consumption1. 1Values are means ± SEM; n = 25 on vascular function measures for 8-h post-ingestion, and 
n = 27 on vascular function measures for 5-h post-ingestion, n = 23 on blood biochemistry for 8-h post-
ingestion, and n = 26 on blood chemistry for 5-h post-ingestion. Baselines were significantly different (p ≤ 0.05) 
from one another, apart from glucose for 5-h post-ingestion and FMD both for 5-h and 8-h post-ingestion. 
Different superscript letters within a row refers to treatment groups different from one another, p ≤ 0.05. All 
data were logtransformed apart from FMD, AI@HR75 and SI. AI@HR75, augmentation index when corrected 
for a heart rate of 75 mm Hg DBP, diastolic blood pressure; NEFA, non-esterified fatty acid; PP, pulse pressure; 
SBP, systolic blood pressure; SI, stiffness index; TAG, triacylglycerol; Δ change from baseline. 2Overall between-
group treatment effects for each Δ obtained by using linear mixed-model ANOVA with baseline values for the 
variable of interest, and prognostic values such as age, gender, BMI. Tukey-Kramer’s correction was used as post 
hoc anaysis to adjust for multiple testing. The values with difference superscript letters are significantly different 
from each other.
Figure 3. 8-h postprandial FMD response in men and women with pre- and mild hypertension after 
consuming whey protein, Ca-caseinate and maltodextrin. †p = 0.017 between whey and maltodextrin at 5-h 
post-ingestion according to post hoc test (one-way repeated-measures ANOVA). Values are means ± SEM, 
n = 25. FMD, flow-mediated dilation.
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compared to expected elevated responses after maltodextrin, which is in contrast with other studies, where whey 
protein induced a smaller glucose response compared with casein12,34. However, whey protein ingestion resulted 
in similar serum insulin concentrations to maltodextrin (iAUC 0–8 h whey: 1346.6 ± 112.8, iAUC 0–8 h malto-
dextrin: 1482.7 ± 150 pmol/L) both being significantly higher than after Ca-caseinate ingestion. Whey protein 
is considered as an insulin-secretagogue, which may be due to its effects on pancreatic β-cells35 and/or incretin 
hormones36. Likewise, whey protein has a high branch-chained amino acid content and because of its fast absorp-
tion rates, triggers rapid and high insulin secretion. Insulin is intimately involved with lipolysis37, which may 
explain why whey protein and maltodextrin resulted in a greater NEFA suppression 5 h after breakfast ingestion 
compared with Ca-caseinate. This may be a consequence of the slower rate of Ca-caseinate absorption and thus 
a less rapid suppression of lipolysis through reduced insulin release. This finding is in contrast with a study of 
Holmer-Jensen et al. in which a smaller NEFA suppression was observed after a meal containing whey protein11, 
and with Bendtsen and co-workers’ study where NEFA concentration was higher after whey protein ingestion 
compared with intact and hydrolysed casein38. Furthermore, surprisingly we found significantly higher circulat-
ing TAG concentrations after whey protein ingestion compared with Ca-caseinate and maltodextrin. Elevated 
postprandial TAG is considered a CVD risk factor and appears to be more discriminatory than fasting TAG10. 
Yet, high postprandial TAG after whey protein ingestion in our trial did not seem to impact detrimentally on 
BP or vascular function. In contrast, previous RCTs found lowering of postprandial TAG after whey protein 
consumption compared with casein or other dietary proteins such as cod12,39. Nevertheless, postprandial TAG 
response does not provide a detailed insight into postprandial lipoprotein metabolism and other biomarkers such 
as apolipoproteins and particle number (evaluated by apo B-48 response) and size which may have provided a 
more complete evaluation of the postprandial effects of the interventions. However, it is puzzling that long-term 
whey protein consumption was found to decrease fasting TAG in our chronic study8, yet we report increased 
postprandial TAG concentrations  in this postprandial trial. It is of note that the beneficial effect of Ca-caseinate 
on TAG may be due to its high Ca content (more than 2.7-fold higher than whey protein). Evidence suggests 
that Ca can interact with fatty acids, particularly saturated fatty acids within the gut and speculatively forming 
insoluble soaps and/or formation of insoluble aggregation with phosphorus and biles acids and fatty acids, which 
are resistant to digestion and are subsequently excreted in the faeces40. These have been proposed as potential 
mechanisms by which dairy products, particularly cheese which contains high Ca levels, can reduce circulatory 
lipid concentrations41.
A potential limitation of this study is the lack of the measurements of faecal fat and Ca excretion, which would 
have helped to elucidate whether this potential mechanism could have affected postprandial lipid metabolism. 
Maltodextrin was used as a source of carbohydrate in this study as it had a lack of flavour, easy dissolvability and 
acceptable to the participants. However postprandial responses may have varied if different types of carbohydrate 
were used (such as starch or glucose). Moreover, if a test meal with a different nutritional composition was con-
sumed, the acute resonses may have differed from that reported in this study. The dairy proteins used in this study 
were unhydrolysed and in a form similar to that found in dairy foods, it would therefore be predicted that the 
Figure 4. 8-h postprandial glucose (A), insulin (B), NEFA (C) and TAG (D) response in men and women 
with pre- and mild hypertension after consuming whey protein, Ca-caseinate and maltodextrin. Values are 
means ± SEM, n = 23. h, hour; NEFA, non-esterified fatty acid; TAG, triacylglycerol. (A) ‡Maltodextrin vs. 
whey protein and Ca-caseinate p < 0.001. (B) ‡At 30 min whey protein vs. Ca-caseinate p < 0.001, whey protein 
vs. maltodextrin p = 0.003, maltodextrin vs. Ca-caseinate p < 0.001; at 60 min whey protein vs. maltodextrin 
p = 0.015, Ca-caseinate vs. maltodextrin p < 0.001; at 90 min whey protein vs. Ca-caseinate p = 0.014, whey 
protein vs. maltodextrin p = 0.049; at 360 min whey protein vs Ca-caseinate p < 0.001, Ca-caseinate vs. 
maltodextrin p = 0.001. (C) ‡Ca- caseinate vs. whey protein and maltodextrin p < 0.05. (D) ‡Whey protein vs. 
Ca-caseinate and maltodextrin p < 0.05.
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equivalent quantity of dairy protein consumed as a food would have elicited similar vascular effect as the isolated 
dairy proteins, however this would need confirmation in further studies. Furthermore, the current trial was not 
powered to detect changes in serum ACE activity so the lack of significant effect of this analyte may have been a 
consequence of small sampe size.
Perspectives. We observed a significant fall in SBP after 28 g whey protein co-ingestion with an isoenergetic, 
high-fat breakfast compared with Ca-caseinate and maltodextrin in individuals with pre- and mild hypertension. 
Concomitantly, whey protein appeared to improve measures of postprandial arterial stiffness throughout the 
8 h postprandial period compared with maltodextrin. Furthermore, although whey protein consumption did 
not improve endothelial-dependent vasodilation significantly compared with baseline, or the other interven-
tions; whey protein significantly attenuated the reduction in FMD compared with Ca-caseinate and maltodextrin 
ingestion. Whey protein induced a similar insulin response and NEFA suppression, to maltodextrin, but a lower 
glucose response. Whereas Ca-caseinate ingestion resulted in significantly lower insulin response which was 
reflected in a reduced NEFA suppression compared with whey protein and maltodextrin, and induced lower 
postprandial TAG concentrations compared with whey protein. Further research should elucidate the underlying 
mechanism of the short- and long-term effects of whey protein on postprandial AI, insulin and TAG.
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